Lannett Announces Fiscal 2018 Third-Quarter Financial Results

PHILADELPHIA, May 7, 2018 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2018 third quarter ended March 31, 2018.

“We continue to make good progress executing on our strategic initiatives,” said Tim Crew, chief executive officer of Lannett. “During the quarter, we acquired five products from UCB and entered into three new agreements with our strategic alliance partners, which I am delighted to report have progressed and already created new revenue streams. To further build out our product offering, earlier today we announced the acquisition of a portfolio of primarily oral solution medications, comprised of 23 approved Abbreviated New Drug Applications (ANDAs) and one pending ANDA. Moreover, we have re-aligned and added depth and expertise to the management team, resulting in improved manufacturing output and a re-invigorated marketing plan to launch our products.

“With regard to our third quarter financial results, profitability on an adjusted basis exceeded our expectations. Our financial performance reflected the discipline of lower adjusted operating expenses and a mix of positive and negative sales variances to a few of our key products.

“Looking ahead, our plan is to launch over the next several weeks, and into fiscal 2019, a number of our previously approved and recently acquired or in-licensed products. While these launches will have a marginal financial benefit to our fiscal fourth quarter performance, we expect a more substantive impact on fiscal 2019 financial results. Also, we continue to be engaged in numerous discussions with existing and new potential partners to add even more products to our portfolio that will further diversify our revenues, provide affordable alternatives for our customers, and enhance our efficiencies and bottom line.”

For the fiscal 2018 third quarter, on a GAAP basis, net sales were $174.4 million compared with $165.7 million for the third quarter of fiscal 2017. During the third quarter of last year, the company recorded a $4.0 million adjustment to a settlement agreement with one of its customers, which resulted in total net sales for the prior-year period of $161.7 million. Gross profit was $67.1 million, or 38% of total net sales, compared with $72.4 million, or 45% of total net sales. Research and development (R&D) expenses of $2.7 million benefited from a cancelled order for pre-launch inventory totaling $3.8 million. This compares with R&D expenses of $8.3 million for the fiscal 2017 third quarter. Selling, general and administrative (SG&A) expenses decreased to $14.1 million from $17.6 million. Restructuring expenses were $1.4 million compared with $1.6 million. Following a strategic evaluation of its pipeline, the company sold rights to a pipeline product to its development partner for an upfront payment and future payments based on FDA approval and other milestones. As a result of this transaction, the company recorded a loss on sale of intangible asset of $15.5 million in the current year third quarter. In the prior-year third quarter, the company recorded acquisition and integration-related expenses of $1.3 million. Operating income was $33.3 million compared with $43.6 million. Interest expense was $22.8 million compared with $22.4 million for the third quarter of fiscal 2017. The company recorded an income tax benefit of $2.3 million versus income tax expense of $7.3 million in the prior-year period. Net income attributable to Lannett was $12.8 million, or $0.33 per diluted share, compared with $14.9 million, or $0.40 per diluted share, for the fiscal 2017 third quarter.

For the fiscal 2018 third reported on a Non-GAAP basis, adjusted net sales were $174.4 million compared with $165.7 million for the third quarter of fiscal 2017. Adjusted gross profit was $76.7 million, or 44% of adjusted net sales, compared with $85.5 million, or 52% of adjusted net sales, for the prior-year third quarter. Adjusted R&D expenses were $2.7 million compared with $8.3 million. Adjusted SG&A expenses were $14.1 million compared with $17.3 million. Adjusted operating income was $59.8 million compared with $59.9 million for the prior-year third quarter. Adjusted interest expense declined to $16.2 million from $16.7 million for the third quarter of fiscal 2017. Adjusted income tax expense was $13.2 million compared with $15.0 million in the prior-year period. Adjusted net income attributable to Lannett was $30.5 million, or $0.80 per diluted share, compared with $29.2 million, or $0.77 per diluted share, for the fiscal 2017 third quarter.

Guidance for Fiscal 2018

Based on its current outlook, the company’s fiscal 2018 full year net sales and adjusted profitability is unchanged, although individual elements of its financial guidance from February 7, 2018 have been revised, as follows.

 GAAP Adjusted ---- -------- Net sales $685 million to $695 million, updated from $680 million to $700 million $685 million to $695 million, updated from $680 million to $700 million --------- ----------------------------------- ----------------------------------- Gross margin % Approximately 42%, down from 42% to Approximately 48%, down from 48% to 43% 49% ------------- ----------------------------------- ----------------------------------- R&D expense $30 million to $32 million, down from $36 million to $38 million $30 million to $32 million, down from $36 million to $38 million ----------- ----------------------------------- ----------------------------------- SG&A expense $79 million to $81 million, Unchanged $71 million to $73 million, Unchanged ------------ ----------------------------------- ----------------------------------- Integration and restructuring related expense $4 million to $5 million, unchanged $ -- ---------------- ----------------------------------- ---- Loss on Sale of Intangible asset $16 million $ -- ----------------- ----------- ---- Interest expense and other $79 million to $80 million, Up from $77 million to $78 million $62 million to $63 million, Unchanged ---------------- ----------------------------------- ----------------------------------- Effective tax rate Approximately 35%, down from Approximately 28%, up from approximately 39% approximately 27% ------------------ ----------------------------- --------------------------- Capital Approximately $50 million, changed Approximately $50 million, changed expenditures from the range of $45 million to from the range of $45 million to $55 million $55 million ------------- ----------------------------------- ----------------------------------- 

Conference Call Information and Forward-Looking Statements
Later today, the company will host a conference call at 4:30 p.m. ET to review its results of operations for its fiscal 2018 third quarter ended March 31, 2018. The conference call will be available to interested parties by dialing 866-436-9172 from the U.S. or Canada, or 630-691-2760 from international locations, passcode 46898785. The call will be broadcast via the Internet at www.lannett.com. Listeners are encouraged to visit the website at least 10 minutes prior to the start of the scheduled presentation to register, download and install any necessary audio software. A playback of the call will be archived and accessible on the same website for at least three months.

Discussion during the conference call may include forward-looking statements regarding such topics as, but not limited to, the company’s financial status and performance, regulatory and operational developments, and any comments the company may make about its future plans or prospects in response to questions from participants on the conference call.

Use of Non-GAAP Financial Measures
This news release contains references to Non-GAAP financial measures, which are financial measures that are not prepared in conformity with United States generally accepted accounting principles (U.S. GAAP). Management uses these measures internally for evaluating its operating performance. The Company’s management believes that the presentation of Non-GAAP financial measures provides useful supplementary information regarding operational performance, because it enhances an investor’s overall understanding of the financial results for the Company’s core business. Additionally, it provides a basis for the comparison of the financial results for the Company’s core business between current, past and future periods. Non-GAAP financial measures should be considered only as a supplement to, and not as a substitute for or as a superior measure to, financial measures prepared in accordance with U.S. GAAP.

Detailed reconciliations of non-GAAP financial measures to the most directly comparable GAAP financial measures are included with this release.

Non-GAAP financial measures exclude, among others, the effects of (1) amortization of purchased intangibles and other purchase accounting entries, (2) acquisition and integration-related expenses, (3) non-cash interest expense, as well as (4) certain other items considered unusual or non-recurring in nature.

About Lannett Company, Inc.:
Lannett Company, founded in 1942, develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of medical indications - see financial schedule below for net sales by medical indication. For more information, visit the company’s website at www.lannett.com.

This news release contains certain statements of a forward-looking nature relating to future events or future business performance. Any such statements, including, but not limited to, successfully launching and commercializing recently acquired and previously approved products, realizing enhanced efficiencies, successfully consummating transactions with new and existing alliance partners and successfully launching commercializing products included therein, and achieving the financial metrics stated in the company’s guidance for fiscal 2018, whether expressed or implied, are subject to risks and uncertainties which can cause actual results to differ materially from those currently anticipated due to a number of factors which include, but are not limited to, the difficulty in predicting the timing or outcome of FDA or other regulatory approvals or actions, the ability to successfully commercialize products upon approval, including acquired products, and Lannett’s estimated or anticipated future financial results, future inventory levels, future competition or pricing, future levels of operating expenses, product development efforts or performance, and other risk factors discussed in the company’s Form 10-K and other documents filed with the Securities and Exchange Commission from time to time. These forward-looking statements represent the company’s judgment as of the date of this news release. The company disclaims any intent or obligation to update these forward-looking statements.

 Contact: Robert Jaffe Robert Jaffe Co., LLC (424) 288-4098 

FINANCIAL SCHEDULES FOLLOW

 LANNETT COMPANY, INC. CONSOLIDATED BALANCE SHEETS (In thousands, except share and per share data) (Unaudited) March 31, 2018 June 30, 2017 -------------- ------------- ASSETS ------ Current assets: Cash and cash equivalents $114,016 $117,737 Investment securities 9,089 27,091 Accounts receivable, net 238,767 204,066 Inventories 133,290 122,604 Prepaid income taxes 16,563 16,703 Other current assets 10,045 6,592 ------ ----- Total current assets 521,770 494,793 Property, plant and equipment, net 267,398 243,148 Intangible assets, net 420,582 453,861 Goodwill 339,566 339,566 Deferred tax assets 18,713 52,753 Other assets 29,462 19,191 TOTAL ASSETS $1,597,491 $1,603,312 ========== ========== LIABILITIES ----------- Current liabilities: Accounts payable $67,501 $44,720 Accrued expenses 5,832 12,499 Accrued payroll and payroll- related expenses 9,318 4,833 Rebates payable 41,267 44,593 Royalties payable 9,540 3,015 Restructuring liability 3,328 5,431 Settlement liability - 17,000 Short-term borrowings and current portion of long-term debt 66,845 60,117 ------ ------ Total current liabilities 203,631 192,208 Long-term debt, net 784,689 843,530 Other liabilities 2,199 6,452 TOTAL LIABILITIES 990,519 1,042,190 ------- --------- Commitments and contingencies STOCKHOLDERS’ EQUITY -------------------- Common stock ($0.001 par value, 100,000,000 shares authorized; 38,176,302 and 37,528,450 shares issued; 37,305,266 and 36,919,296 shares outstanding at March 31, 2018 and June 30, 2017, respectively) 38 37 Additional paid-in capital 303,376 292,780 Retained earnings 317,823 277,774 Accumulated other comprehensive loss (450) (222) Treasury stock (871,036 and 609,154 shares at March 31, 2018 and June 30, 2017, respectively) (13,815) (9,247) ------- ------ Total stockholders’ equity 606,972 561,122 ------- ------- TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $1,597,491 $1,603,312 ========== ========== 

 LANNETT COMPANY, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) (In thousands, except share and per share data) Three months ended Nine months ended March 31, March 31, --------- --------- 2018 2017 2018 2017 ---- ---- ---- ---- Net sales $174,386 $165,720 $513,652 $498,223 Settlement agreement - (4,000) - (4,000) Total net sales $174,386 $161,720 $513,652 $494,223 -------- -------- -------- -------- Cost of sales 99,036 81,553 267,503 227,527 Amortization of intangibles 8,293 7,737 23,971 24,361 Gross profit 67,057 72,430 222,178 242,335 ------ ------ ------- ------- Operating expenses: Research and development expenses 2,730 8,340 20,861 30,650 Selling, general, and administrative expenses 14,112 17,629 61,643 56,958 Acquisition and integration- related expenses - 1,256 83 3,674 Restructuring expenses 1,421 1,568 2,983 5,332 Loss on sale of intangible asset 15,514 - 15,514 - Intangible asset impairment charges - - - 88,084 --- --- --- ------ Total operating expenses 33,777 28,793 101,084 184,698 ------ ------ ------- ------- Operating income 33,280 43,637 121,094 57,637 ------ ------ ------- ------ Other income (loss): Investment income 719 1,037 4,208 3,085 Interest expense (22,842) (22,373) (64,440) (68,700) Other (662) (35) 2,473 (298) ---- --- ----- ---- Total other loss (22,785) (21,371) (57,759) (65,913) ------- ------- ------- ------- Income (loss) before income tax 10,495 22,266 63,335 (8,276) Income tax expense (benefit) (2,275) 7,337 23,286 (2,003) ------ ----- ------ ------ Net income (loss) 12,770 14,929 40,049 (6,273) Less: Net income attributable to noncontrolling interest - - - 34 --- --- --- --- Net income (loss) attributable to Lannett Company, Inc. $12,770 $14,929 $40,049 $(6,307) ======= ======= ======= ======= Earnings (loss) per common share attributable to Lannett Company, Inc.: Basic $0.34 $0.41 $1.08 $(0.17) Diluted $0.33 $0.40 $1.05 $(0.17) Weighted average common shares outstanding: Basic 37,136,945 36,849,208 37,064,781 36,785,829 Diluted 38,287,005 37,752,304 38,112,193 36,785,829 

 LANNETT COMPANY, INC. RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION (UNAUDITED) (In thousands, except percentages, share and per share data) Three months ended March 31, 2018 --------------------------------- Net sales Cost of Amortization Gross Gross R&D SG&A Acquisition and Restructuring Loss on sale of Operating Other Income Income tax Net income Net income Net income Diluted sales of intangibles Profit Margin % expense expense integration- expenses intangible asset income income before expense attributable to attributable to earnings related (loss) income (benefit) noncontrolling Lannett per share expenses tax interest Company, Inc. (g) --- --- --- -------- --- --- GAAP Reported $174,386 $99,036 $8,293 $67,057 38% $2,730 $14,112 $ - $1,421 15,514 $33,280 $(22,785) $10,495 $(2,275) $12,770 $ - $12,770 $0.33 Adjustments: ------------ Depreciation of Fixed Assets step- up (a) - (1,335) - 1,335 - - - - - 1,335 - 1,335 - 1,335 - 1,335 Amortization of intangibles (b) - - (8,293) 8,293 - - - - - 8,293 - 8,293 - 8,293 - 8,293 Restructuring expenses (c) - - - - - - - (1,421) - 1,421 - 1,421 - 1,421 - 1,421 Loss on sale of intangible asset (d) - - - - - - - - (15,514) 15,514 15,514 - 15,514 - 15,514 Non-cash interest (e) - - - - - - - - - - 6,642 6,642 - 6,642 - 6,642 Tax adjustments (f) - - - - - - - - - - - - 15,508 (15,508) - (15,508) Non-GAAP Adjusted $174,386 $97,701 $ - $76,685 44% $2,730 $14,112 $ - $ - $ - $59,843 $(16,143) $43,700 $13,233 $30,467 $ - $30,467 $0.80 ======== ======= ==================== ======= === ====== ======= ===================== ================== ====================== ======= ======== ======= ======= ======= =================== ======= ===== 

 (a) Relates to depreciation of a fair value step-up in property, plant and equipment related to the acquisition of Kremers Urban Pharmaceuticals, Inc. (“KUPI”) (b) Relates to amortization of purchased intangible assets primarily related to the acquisitions of KUPI and Silarx Pharmaceuticals, Inc. (c) To exclude expenses associated with the 2016 Restructuring Plan (d) To exclude a loss realized on a sale of an intangible asset (e) To exclude non-cash interest expense primarily associated with debt issuance costs (f) To exclude the impact of the revaluation of net long term deferred tax assets related to the Tax Cut and Jobs Act legislation (“2017 Tax Reform”), partially offset by the tax effect of the pre-tax adjustments included at applicable tax rates (g) The weighted average share number for the three months ended March 31, 2018 is 38,287,005 for both the GAAP and the non- GAAP earnings per share calculations 

 LANNETT COMPANY, INC. RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION (UNAUDITED) (In thousands, except percentages, share and per share data) Three months ended March 31, 2017 --------------------------------- Total net Cost of Amortization Gross Gross R&D SG&A Acquisition and Restructuring Operating Other Income Income tax Net income Net income Net income Diluted sales sales of intangibles Profit Margin % expense expense integration- expenses income income before expense attributable to attributable to earnings related (loss) income noncontrolling Lannett per share expenses tax interest Company, Inc. (h) --- --- --- -------- --- --- GAAP Reported $161,720 $81,553 $7,737 $72,430 45% $8,340 $17,629 $1,256 $1,568 $43,637 $(21,371) $22,266 $7,337 $14,929 $ - $14,929 $0.40 Adjustments: ------------ Settlement agreement (a) 4,000 - - 4,000 - - - - 4,000 - 4,000 - 4,000 - 4,000 Depreciation of Fixed Assets step- up (b) - (1,335) - 1,335 - - - - 1,335 - 1,335 - 1,335 - 1,335 Amortization of intangibles (c) - - (7,737) 7,737 - (365) - - 8,102 - 8,102 - 8,102 - 8,102 Acquisition and integration- related expenses (d) - - - - - - (1,256) - 1,256 - 1,256 - 1,256 - 1,256 Restructuring expenses (e) - - - - - - - (1,568) 1,568 - 1,568 - 1,568 - 1,568 Non-cash interest (f) - - - - - - - - - 5,688 5,688 - 5,688 - 5,688 Tax adjustments (g) - - - - - - - - - - - 7,679 (7,679) - (7,679) Non-GAAP Adjusted $165,720 $80,218 $ - $85,502 52% $8,340 $17,264 $ - $ - $59,898 $(15,683) $44,215 $15,016 $29,199 $ - $29,199 $0.77 ======== ======= =================== ======= === ====== ======= =================== =============== ======= ======== ======= ======= ======= ================ ======= ===== 

 (a) Relates to an adjustment to a settlement agreement with a former customer (b) Relates to depreciation of a fair value step-up in property, plant and equipment related to the acquisition of Kremers Urban Pharmaceuticals, Inc. (“KUPI”) (c) Relates to amortization of purchased intangible assets primarily related to the acquisitions of KUPI and Silarx Pharmaceuticals, Inc. (d) Relates to acquisition and integration-related expenses primarily related to the acquisition of KUPI (e) To exclude expenses associated with the 2016 Restructuring Plan (f) To exclude non-cash interest expense primarily associated with debt issuance costs (g) The tax effect of the pre-tax adjustments included at applicable tax rates (h) The weighted average share number for the three months ended March 31, 2017 is 37,752,304 for both the GAAP and the non-GAAP earnings per share calculations 

 LANNETT COMPANY, INC. RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION (UNAUDITED) (In thousands, except percentages, share and per share data) Nine months ended March 31, 2018 -------------------------------- Net Cost of Amortization Gross Gross R&D SG&A Acquisition and Restructuring Loss on sale of Operating Other Income Income tax Net income Net income Net income Diluted sales sales of intangibles Profit Margin % expense expense integration- expenses intangible asset income income before expense attributable to attributable to earnings related (loss) income noncontrolling Lannett per share expenses tax interest Company, Inc. (j) --- --- --- -------- --- --- GAAP Reported $513,652 $267,503 $23,971 $222,178 43% $20,861 $61,643 $83 $2,983 $15,514 $121,094 $(57,759) $63,335 $23,286 $40,049 $ - $40,049 $1.05 Adjustments: ------------ Depreciation of Fixed Assets step- up (a) - (4,005) - 4,005 - - - - - 4,005 - 4,005 - 4,005 - 4,005 Amortization of intangibles (b) - - (23,971) 23,971 - (582) - - - 24,553 - 24,553 - 24,553 - 24,553 Acquisition and integration- related expenses (c) - - - - - - (83) - - 83 - 83 - 83 - 83 Restructuring expenses (d) - - - - - - - (2,983) - 2,983 - 2,983 - 2,983 - 2,983 Loss on sale of intangible asset (e) - - - - - - - - (15,514) 15,514 15,514 - 15,514 - 15,514 Non-cash interest (f) - - - - - - - - - - 15,656 15,656 - 15,656 - 15,656 Litigation settlement gain (g) - - - - - - - - - - (3,500) (3,500) - (3,500) - (3,500) Other (h) - - - - - (7,405) - - - 7,405 - 7,405 - 7,405 - 7,405 Tax adjustments (i) - - - - - - - - - - - - 12,978 (12,978) - (12,978) Non-GAAP Adjusted $513,652 $263,498 $ - $250,154 49% $20,861 $53,656 $ - $ - $ - $175,637 $(45,603) $130,034 $36,264 $93,770 $ - $93,770 $2.46 ======== ======== =================== ======== === ======= ======= =================== =============== ================== ======== ======== ======== ======= ======= ================ ======= ===== 

 (a) Relates to depreciation of a fair value step-up in property, plant and equipment related to the acquisition of Kremers Urban Pharmaceuticals, Inc. (“KUPI”) (b) Relates to amortization of purchased intangible assets primarily related to the acquisitions of KUPI and Silarx Pharmaceuticals, Inc. (c) Relates to acquisition and integration- related expenses primarily related to the acquisition of KUPI (d) To exclude expenses associated with the 2016 Restructuring Plan (e) To exclude a loss realized on a sale of an intangible asset (f) To exclude non- cash interest expense primarily associated with debt issuance costs (g) To exclude a settlement gain associated with patent litigation (h) To exclude separation benefits associated with the former Chief Executive Officer as well as a reversal of indemnified unrecognized tax benefits due to expirations in the statute of limitations, related to the KUPI acquisition (i) To exclude the impact of the revaluation of net long term deferred tax assets related to the Tax Cut and Jobs Act legislation (“2017 Tax Reform”), partially offset by the tax effect of the pre-tax adjustments included at applicable tax rates as well as the reversal of indemnified unrecognized tax benefits related to the KUPI acquisition (j) The weighted average share number for the nine months ended March 31, 2018 is 38,112,193 for both the GAAP and the non- GAAP earnings per share calculations 

 LANNETT COMPANY, INC. RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION (UNAUDITED) (In thousands, except percentages, share and per share data) Nine months ended March 31, 2017 -------------------------------- Total net Cost of Amortization Gross Profit Gross R&D SG&A Acquisition and Restructuring Intangible Operating Other Income Income Net income Net income Net income (loss) Diluted sales sales of intangibles Margin % expense expense integration- expenses asset income income (loss) before tax (loss) attributable to attributable to earnings related expenses impairment (loss) income tax expense noncontrolling Lannett (loss) per charges (benefit) interest Company, Inc. share (k) --- --- --- -------- -------- --------- GAAP Reported $494,223 $227,527 $24,361 $242,335 49% $30,650 $56,958 $3,674 $5,332 $88,084 $57,637 $(65,913) $(8,276) $(2,003) $(6,273) $34 $(6,307) $(0.17) Adjustments: ------------ Settlement agreement (a) 4,000 - - 4,000 - - - - - 4,000 - 4,000 - 4,000 - 4,000 Depreciation of Fixed Assets step- up (b) - (3,075) - 3,075 - - - - - 3,075 - 3,075 - 3,075 - 3,075 Amortization of Inventory step-up (c) - (1,938) - 1,938 - - - - - 1,938 - 1,938 - 1,938 - 1,938 Amortization of intangibles (d) - - (24,361) 24,361 - (1,095) - - - 25,456 - 25,456 - 25,456 - 25,456 Acquisition and integration- related expenses (e) - - - - - - (3,674) - - 3,674 - 3,674 - 3,674 - 3,674 Restructuring expenses (f) - - - - - - - (5,332) - 5,332 - 5,332 - 5,332 - 5,332 Intangible assets impairment charges (g) - - - - - - - - (88,084) 88,084 - 88,084 - 88,084 - 88,084 Non-cash interest (h) - - - - - - - - - - 15,961 15,961 - 15,961 - 15,961 Other (i) - - - - - (715) - - - 715 - 715 - 715 - 715 Tax adjustments (j) - - - - - - - - - - - - 49,195 (49,195) - (49,195) Non-GAAP Adjusted $498,223 $222,514 $ - $275,709 55% $30,650 $55,148 $ - $ - $ - $189,911 $(49,952) $139,959 $47,192 $92,767 $34 $92,733 $2.46 ======== ======== =================== ======== === ======= ======= ===================== =============== ================= ======== ======== ======== ======= ======= === ======= ===== 

 Relates to an adjustment to a settlement agreement with a former (a) customer Relates to depreciation of a fair value step-up in property, plant and equipment related to the acquisition of Kremers Urban Pharmaceuticals, (b) Inc. (“KUPI”) Relates to amortization of a fair value step-up in (c) inventory r elated to the acquisition of KUPI Relates to amortization of purchased intangible assets primarily related to the acquisitions of KUPI and Silarx Pharmaceuticals, (d) Inc. Relates to acquisition and integration- related expenses primarily related to the acquisition of (e) KUPI To exclude expenses associated with the 2016 Restructuring (f) Plan To exclude impairment charges related to certain intangible assets acquired as part of the KUPI (g) acquisition To exclude non- cash interest expense primarily associated with debt issuance (h) costs Primarily relates to separation expenses associated with a former (i) employee The tax effect of the pre-tax adjustments included at applicable tax (j) rates The weighted average share numbers for the nine months ended March 31, 2017 are 36,785,829 and 37,669,173 for the GAAP and non-GAAP earnings (loss) per share calculations, (k) respectively 

 LANNETT COMPANY, INC. RECONCILIATION OF GAAP TO NON-GAAP ADJUSTED INFORMATION (UNAUDITED) ($ in millions) Fiscal Year 2018 Guidance ------------------------- Non-GAAP GAAP Adjustments Adjusted ---- ----------- -------- Net sales $685 - $695 - $685 - $695 Gross margin percentage approx. 42% 6% (a) approx. 48% R&D expense $30 - $32 - $30 - $32 SG&A expense $79 - $81 ($8) (b) $71 - $73 Integration and Restructuring expense $4 - $5 ($4 - $5) (c) - Loss on Sale of Intangible Asset $16 ($16) (d) - --- ---- Interest expense and other $79 - $80 ($17) (e) $62 - $63 Effective tax rate approx. 35% (7%) (f) approx. 28% Capital expenditures approx. $50 - approx. $50 

 (a) The adjustment primarily reflects amortization of purchased intangible assets and depreciation of a fair value step-up in property, plant and equipment related to the acquisition of Kremers Urban Pharmaceuticals, Inc. (“KUPI”) (b) The adjustment reflects severance benefits to the former chief executive officer, a reversal of indemnified unrecognized tax benefits as well as amortization of purchased intangible assets related to the acquisition of KUPI (c) The adjustment primarily reflects expenses related to the 2016 Restructuring Plan (d) The adjustment reflects a loss on sale of an intangible asset acquired as part of the acquisition of KUPI (e) The adjustment primarily reflects non- cash interest expense associated with debt issuance costs as well as a litigation settlement gain (f) The adjustment primarily reflects the impact of the revaluation of net long term deferred tax assets related to the Tax Cut and Jobs Act legislation (“2017 Tax Reform”) 

 LANNETT COMPANY, INC. NET SALES BY MEDICAL INDICATION Three months ended Nine months ended (in thousands) March 31, March 31, --------- --------- Medical Indication 2018 2017 2018 2017 ------------------ ---- ---- ---- ---- Antibiotic $3,801 $4,474 $10,701 $13,047 Anti-Psychosis 9,336 14,433 47,127 47,119 Cardiovascular 18,514 14,815 39,955 39,484 Central Nervous System 8,395 11,124 24,137 32,028 Gallstone 3,828 11,157 15,674 37,465 Gastrointestinal 16,562 19,441 46,171 56,470 Glaucoma 875 4,868 5,706 15,962 Migraine 12,888 7,043 43,387 22,066 Muscle Relaxant 3,299 3,673 10,309 10,208 Pain Management 6,594 6,085 18,483 20,132 Respiratory 2,324 4,256 6,200 9,426 Thyroid Deficiency 69,975 44,999 185,983 130,267 Urinary 33 2,619 5,870 12,413 Other 12,376 14,555 38,178 36,870 Contract Manufacturing revenue 5,586 2,178 15,771 15,266 ----- ----- ------ ------ Net Sales 174,386 165,720 513,652 498,223 ------- ------- ------- ------- Settlement agreement - (4,000) - (4,000) Total Net Sales $174,386 $161,720 $513,652 $494,223 ======== ======== ======== ========